Suggestions
Rachel King
Biotechnology Executive
Rachel King is a prominent figure in the biotechnology sector, currently serving as a member of the Board of Directors at Novavax, Inc. since 2018. She is also the co-founder and former CEO of GlycoMimetics, Inc., a biotechnology company focused on developing therapies for cancer and inflammatory diseases. King's extensive career spans over three decades, during which she has held various significant roles in both executive leadership and venture capital.
Professional Background
- Novavax, Inc.: Rachel joined the board in November 2018, bringing her vast experience in biotechnology and pharmaceuticals to the company, which specializes in vaccine development for serious infectious diseases.17
- GlycoMimetics, Inc.: She co-founded this clinical-stage biotechnology company in 2003 and served as its CEO until August 2021.23
- Biotechnology Innovation Organization (BIO): King has been an influential leader within BIO, serving as CEO since November 2022 and previously holding various positions including Chair of the Board.56
Previous Experience
- New Enterprise Associates (NEA): Before founding GlycoMimetics, she was an Executive in Residence at NEA, a leading venture capital firm.17
- Novartis Corporation: Rachel held the position of Senior Vice President at Novartis from 1999 to 2001, contributing to significant advancements in pharmaceutical development.23
- Genetic Therapy, Inc.: She spent ten years with this company, which included leading it through its initial public offering and eventual acquisition by Novartis, where she continued to serve as CEO of the subsidiary.48
Education
Rachel King earned her Bachelor of Arts degree from Dartmouth College and her MBA from Harvard Business School, equipping her with a strong foundation for her entrepreneurial and executive endeavors in biotechnology.24
Current Roles
In addition to her role at Novavax, Rachel serves on several boards including:
- University of Maryland BioPark
- MdBio, Inc.
- Learning Undefeated, Inc.
Her leadership and expertise are recognized across the industry, making her a key player in advancing biotechnological innovations and addressing critical health challenges globally.37
